Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Combination Therapy of Rosuvastatin and Fenofibrate Versus Rosuvastatin Monotherapy in Mixed Dyslipidemia Patients

NCT02262143 is registered in ClinicalTrials.gov with IlDong Pharmaceutical Co Ltd as lead sponsor.

NCT NCT02262143
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02262143 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Combination Therapy of Rosuvastatin and Fenofibrate Versus Rosuvastatin Monotherapy in Mixed Dyslipidemia Patients
Lead sponsor
IlDong Pharmaceutical Co Ltd
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2014
Completion date
June 30, 2017
Enrollment
362 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

mixed dyslipidemias